| Subject: | FDA Issues Safety Alert for Xigris (drotrecogin alfa activated) Use |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 29 Mar 2005 - 10:00 am |
| The FDA and Eli Lilly have issued notice to healthcare professionals regarding Xigris (drotrecogin alfa - activated) use in patients with severe sepsis. Xigris is a biological therapeutic agent that is used to treat adult patients with severe sepsis who are at high risk of death. The FDA states that the warning component of the labeling for Xigris has been revised to indicate patients with single organ dysfunction and recent surgery who are at high risk for mortality should be carefully... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
